thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 16, 2026

FDA rejects Summit’s ivonescimab application over survival evidence

The agency also approved treatments for kidney and neuromuscular disease, authorized at-home Igalmi use and cleared two tubeless insulin-delivery systems.

  • Updated
  • Read from 12 articles, 7 publications
  • B P +1

Today in brief

The FDA rejected Summit Therapeutics’ ivonescimab application for previously treated EGFR-mutated lung cancer, saying the trial did not establish a favorable benefit-risk profile.12 The agency approved Roche’s Gazyva for primary membranous nephropathy, AstraZeneca’s Klygefa for generalized myasthenia gravis and at-home use of Teva’s Igalmi for agitation.345 AstraZeneca’s Imfinzi combination was approved around surgery for certain patients with muscle-invasive bladder cancer.6

FDA rejects Summit’s ivonescimab application

The FDA sent Summit Therapeutics a complete response letter rejecting ivonescimab with chemotherapy for previously treated, locally advanced or metastatic EGFR-mutated non-small cell lung cancer.12 The Phase 3 HARMONi trial met its progression-free survival endpoint, but its primary overall-survival analysis was not statistically significant.2 Median overall survival was 16.8 months with ivonescimab and chemotherapy and 14.0 months with chemotherapy alone.2

The FDA said progression-free survival without a statistically significant overall-survival gain did not establish a favorable benefit-risk profile.12 Among Western participants followed longer, the survival hazard ratio was 0.78, with a nominal P value of .0332. That result did not change the primary analysis.2 Summit said it will continue developing ivonescimab, which remains unapproved in its licensed territories, including the United States and Europe.2

Gazyva approved for primary membranous nephropathy

The FDA approved Roche’s Gazyva, or obinutuzumab, to induce proteinuria remission in adults with primary membranous nephropathy at risk of disease progression.3 In the 142-person Phase 3 MAJESTY trial, complete remission at 104 weeks occurred in 36.1% of patients taking Gazyva and 5.7% taking tacrolimus.3

Overall remission at 104 weeks was 50% with Gazyva and 12.9% with tacrolimus.3 Roche called Gazyva the first FDA-approved treatment for the disease. The FDA is also reviewing it for systemic lupus erythematosus, and a decision is expected by December 2026.3

Klygefa approved for antibody-positive myasthenia gravis

The FDA approved AstraZeneca’s Klygefa, or gefurulimab, for adults with generalized myasthenia gravis who test positive for acetylcholine receptor antibodies.4 Patients use an autoinjector to give themselves the C5 inhibitor under the skin once a week.4

In the 260-person, 26-week PREVAIL trial, Klygefa improved the MG-ADL score by 1.6 points more than placebo at week 26.4 The trial did not compare Klygefa with other myasthenia gravis treatments, so its relative performance is unknown.4

Imfinzi combination approved around bladder cancer surgery

The FDA approved AstraZeneca’s Imfinzi with enfortumab vedotin before surgery, followed by Imfinzi alone, for adults with muscle-invasive bladder cancer who cannot or will not receive cisplatin-based chemotherapy.6 In the Phase 3 VOLGA study, the regimen reduced the combined risk of progression, recurrence, surgery not taking place or death by 49% versus cystectomy with or without approved adjuvant treatment.6

Estimated two-year event-free survival was 64% with the combination and 45% with the comparison treatment.6 Grade 3 or 4 adverse events from any cause occurred in 64% of the combination group and 44% of the comparison group.6

FDA allows at-home Igalmi use for agitation

The FDA approved Teva’s Igalmi sublingual film for adults experiencing agitation linked to schizophrenia, schizoaffective disorder or bipolar I or II disorder.5 In the 12-week Serenity At-Home study, tolerability remained consistent with repeated dosing, and no participants stopped treatment because of tolerability.5

Also worth knowing

  • The UK MHRA launched its Women’s Health Programme to address evidence gaps and assess whether medicine and device risks and benefits differ for women. An analysis of 4,616 UK trial applications found pregnant women represented in 1.1% of trials and breastfeeding women in 0.6%.7

  • Representatives John Moolenaar and Debbie Dingell introduced the proposed Biotech Investment National Security Act, which would require Treasury review of US pharmaceutical licensing agreements, joint ventures and equity investments involving Chinese partners.8

  • The FDA cleared tubeless insulin-delivery systems from MiniMed and Tandem, which plan US launches in 2027.91011

  • B

    The FDA’s Rare Disease Framework Initiative seeks more consistent review practices across its drug, biologics and device centers. The agency is accepting public comments through December 11, 2026.12

Also published